Currently out of the existing stock ratings of Robyn Karnauskas, 304 are a BUY (84.68%), 54 are a HOLD (15.04%), 1 are a SELL (0.28%).

Robyn Karnauskas

Work Performance Price Targets & Ratings Chart

Analyst Robyn Karnauskas, carries an average stock price target met ratio of 50.9% that have a potential upside of 41.87% achieved within 346 days. Previously, Robyn Karnauskas worked at TRUIST.

Robyn Karnauskas’s has documented 734 price targets and ratings displayed on 45 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on TRML, Tourmaline Bio at 09-Sep-2025.

Wall Street Analyst Robyn Karnauskas

Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.

Average potential price target upside

of $451.73 (76.78%) on BTAI (BIOXCEL THERAPEUTICS).
of $132.08 (23.76%) on REGN (REGENERON PHARMACEUTICALS).
of $78.35 (14.68%) on LLY (ELI LILLY AND COMPANY).

ABBV AbbVie ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BTAI BioXcel Therapeutics DCPH Deciphera Pharmaceuticals LLC GILD Gilead Sciences IMVT Immunovant KOD Kodiak Sciences PTCT PTC Therapeutics RCUS Arcus Biosciences REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals APLT Applied Therapeutics BMY Bristol-Myers Squibb Company DRNA Dicerna Pharmaceuticals FATE Fate Therapeutics INFI Infinity Pharmaceuticals MRK Merck mpany PFE Pfizer ASMB Assembly Biosciences NCNA NuCana PLC SRPT Sarepta Therapeutics CELG Celgene OPT Opthea Ltd ROIV Roivant Sciences Ltd TIL Instil Bio MEIP MEI Pharma MNTA Momenta Pharmaceuticals LLY Eli Lilly and Company QURE Uniqure NV CHRS Coherus BioSciences CRIS Curis ABSI Absci Corp BMEA Biomea Fusion EPZM Epizyme OABI OmniAb RYZB RayzeBio, Common Stock TRML Tourmaline Bio ABCL Abcellera Biologics ATNX Athenex FPRX Five Prime Therapeutics KDMN Kadmon Holdings RDUS Schnitzer Steel Industries

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Christopher Raymond (RAYMOND JAMES)